pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 13·1 min read
save

CDC says hantavirus risk to public remains low despite cruise ship outbreak

May 13, 2026·read at STAT ↗Neutral

Two CDC doctors told reporters the risk of hantavirus to the general public is low and that the agency is engaged at every step of the response.

They outlined a coordinated effort that includes state and local health authorities, federal partners and international health agencies to monitor and manage the situation on the cruise ship.

While some infectious‑disease experts have suggested the CDC’s actions lag behind those of the World Health Organization, CDC officials emphasized that their priority is protecting passengers on the ship and American communities.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Hantavirus risk remains low, CDC says, citing its ‘playbook’ response”

read at STAT ↗
732 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2Emory UniversityRISING
topics
Cardiology4Endocrinology & Metabolism2Infectious Disease

related stories

  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • May 12Supreme Court extends mifepristone deadlineSTAT
  • 4d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Sep 21Are healthcare systems really ready for GLP-1s?BioPharma Dive
  • Sep 15Businesses can now apply for NIH fundingSTAT